We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About iOnctura Stock

Invest in or calculate the value of your shares in iOnctura or other pre-IPO companies through EquityZen's platform.

Get Started

iOnctura Stock (IOON)

iOnctura is a clinical-stage biotechnology company that specializes in developing treatments for cancer.

About iOnctura Stock

Founded

2017

Industries

Software, Artificial Intelligence, Data and Analytics

iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies by developing novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology.

iOnctura Press Mentions

Stay in the know about the latest news on iOnctura

iOnctura Management

Leadership team at iOnctura

Non Executive Chair of the Board of Directors

Joanna C. Horobin

Board Member

Roel Bulthuis

Locked Features

Join now and verify your accreditation status to gain access to:

  • iOnctura current valuation
  • iOnctura stock price
  • Available deals in iOnctura and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in iOnctura stock?

Accredited investors can buy pre-IPO stock in companies like iOnctura through EquityZen funds. These investments are made available by existing iOnctura shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell iOnctura stock?

Shareholders can sell their iOnctura stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."